<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02343627</url>
  </required_header>
  <id_info>
    <org_study_id>NVXT 1405</org_study_id>
    <nct_id>NCT02343627</nct_id>
  </id_info>
  <brief_title>Safety and Efficacy of NVXT Solution in Mild-to-Moderate Fungal Infection of the Toe Nail</brief_title>
  <official_title>A Randomized, Double-Blind, Placebo-Controlled, Pilot Study to Assess the Safety and Efficacy of NVXT Solution in Patients With Mild-to-Moderate Fungal Infection of the Toe Nail</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Taro Pharmaceuticals USA</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Taro Pharmaceuticals USA</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will examine the safety, tolerability and efficacy of NVXT in a new formulation in
      patients with mild-to-moderate fungal infection of the toe nail.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This Phase IIa pilot multiple-dose study will examine the safety, tolerability and efficacy
      of NVXT in a new formulation in patients with mild-to-moderate fungal infection of the toe
      nail.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>December 2014</start_date>
  <completion_date type="Actual">January 2016</completion_date>
  <primary_completion_date type="Actual">January 2016</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>negative fungal culture</measure>
    <time_frame>28 days</time_frame>
    <description>To assess negative fungal culture after repeated once-daily topical applications for 28 days</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>negative fungal culture</measure>
    <time_frame>60 days</time_frame>
    <description>To assess negative fungal culture after repeated once-daily topical applications for 60 days</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>negative fungal culture</measure>
    <time_frame>90 days</time_frame>
    <description>To assess negative fungal culture at 30 days after end of 60 day treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>negative fungal culture</measure>
    <time_frame>180 days</time_frame>
    <description>To assess negative fungal culture at 120 days after end of 60 day treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>negative fungal culture</measure>
    <time_frame>270 days</time_frame>
    <description>To assess negative fungal culture at 210 days after end of 60 day treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>negative fungal culture</measure>
    <time_frame>360 days</time_frame>
    <description>To assess negative fungal culture at 300 days after end of 60 day treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mycological cure (negative KOH test AND a negative fungal culture)</measure>
    <time_frame>90 days</time_frame>
    <description>To assess mycological cure (negative KOH test AND a negative fungal culture) at visit conducted 30 days after end of 60 day treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mycological cure (negative KOH test AND a negative fungal culture)</measure>
    <time_frame>180 days</time_frame>
    <description>To assess mycological cure (negative KOH test AND a negative fungal culture) at visit conducted 120 days after end of 60 day treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mycological cure (negative KOH test AND a negative fungal culture)</measure>
    <time_frame>270 days</time_frame>
    <description>To assess mycological cure (negative KOH test AND a negative fungal culture) at visit conducted 210 days after end of 60 day treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mycological cure</measure>
    <time_frame>360 days</time_frame>
    <description>To assess mycological cure (negative KOH test AND a negative fungal culture) at visit conducted 300 days after end of 60 day treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Complete cure (negative KOH test AND a negative fungal culture, and 0% nail involvement by visual assessment)</measure>
    <time_frame>90 days</time_frame>
    <description>To assess the complete cure (negative KOH test AND a negative fungal culture, and 0% nail involvement by visual assessment) at visit conducted 30 days after the end of 60 day treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Complete cure (negative KOH test AND a negative fungal culture, and 0% nail involvement by visual assessment)</measure>
    <time_frame>180 days</time_frame>
    <description>To assess the complete cure (negative KOH test AND a negative fungal culture and 0% nail involvement by visual assessment) at visit conducted 120 days after the end of 60 day treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Complete cure (negative KOH test AND a negative fungal culture, and 0% nail involvement by visual assessment)</measure>
    <time_frame>270 days</time_frame>
    <description>To assess the complete cure (negative KOH test AND a negative fungal culture and 0% nail involvement by visual assessment) at visit conducted 210 days after the end of 60 day treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Complete cure (negative KOH test AND a negative fungal culture, and 0% nail involvement by visual assessment)</measure>
    <time_frame>360 days</time_frame>
    <description>To assess the complete cure (negative KOH test AND a negative fungal culture and 0% nail involvement by visual assessment) at visit conducted 300 days after the end of 60 day treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Therapeutic success (negative KOH test AND a negative fungal culture, ≤5% nail involvement or 50% improvement in nail involvement by visual assessment)</measure>
    <time_frame>90 days</time_frame>
    <description>To assess the therapeutic success (negative KOH test AND a negative fungal culture, ≤5% nail involvement or 50% improvement in nail involvement by visual assessment) at visit conducted 30 days after end of 60 day treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Therapeutic success (negative KOH test AND a negative fungal culture, ≤5% nail involvement or 50% improvement in nail involvement by visual assessment)</measure>
    <time_frame>180 days</time_frame>
    <description>To assess the therapeutic success (negative KOH test AND a negative fungal culture, ≤5% nail involvement or 50% improvement in nail involvement by visual assessment) at visit conducted 120 days after end of 60 day treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Therapeutic success (negative KOH test AND a negative fungal culture, ≤5% nail involvement or 50% improvement in nail involvement by visual assessment)</measure>
    <time_frame>270 days</time_frame>
    <description>To assess the therapeutic success (negative KOH test AND a negative fungal culture, ≤5% nail involvement or 50% improvement in nail involvement by visual assessment) at visit conducted 210 days after end of 60 day treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Therapeutic success (negative KOH test AND a negative fungal culture, ≤5% nail involvement or 50% improvement in nail involvement by visual assessment)</measure>
    <time_frame>360 days</time_frame>
    <description>To assess the therapeutic success (negative KOH test AND a negative fungal culture, ≤5% nail involvement or 50% improvement in nail involvement by visual assessment) at visit conducted 300 days after end of 60 day treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical cure (0% nail involvement by visual assessment)</measure>
    <time_frame>360 days</time_frame>
    <description>To evaluate a rate of clinical cure (0% nail involvement by visual assessment) during 300 days after the end of 60 day treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Nail involvement (rate of change in nail involvement (%) by visual assessment)</measure>
    <time_frame>360 days</time_frame>
    <description>To evaluate a rate of change in nail involvement (%) by visual assessment during 300 days after the end of 60 day treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Nail condition/appearance (grading of nail response)</measure>
    <time_frame>90 days</time_frame>
    <description>To evaluate grading of nail response at visit conducted 30 days after end of 60 day treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Nail condition/appearance (grading of nail response)</measure>
    <time_frame>180 days</time_frame>
    <description>To evaluate grading of nail condition/appearance (1.Poorer, 2.No change; 3.Slight improvement, 4.Strong improvement) self-assessed by patients at visit conducted 120 days after end of 60 day treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Nail condition/appearance (grading of nail response)</measure>
    <time_frame>270 days</time_frame>
    <description>To evaluate grading of nail condition/appearance (1.Poorer, 2.No change; 3.Slight improvement, 4.Strong improvement) self-assessed by patients at visit conducted 210 days after end of 60 day treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Nail condition/appearance (grading of nail response)</measure>
    <time_frame>360 days</time_frame>
    <description>To evaluate grading of nail condition/appearance (1.Poorer, 2.No change; 3.Slight improvement, 4.Strong improvement) self-assessed by patients at visit conducted 300 days after end of 60 day treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants with Adverse Events</measure>
    <time_frame>60 days</time_frame>
    <description>To evaluate the number participants with adverse events</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants with application site reactions</measure>
    <time_frame>360 days</time_frame>
    <description>To evaluate the number participants with application site reactions such as inflammation and irritation</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">48</enrollment>
  <condition>Onychomycosis</condition>
  <arm_group>
    <arm_group_label>NVXT Solution</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>NVXT Solution once daily for 60 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Vehicle of test product</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Vehicle of test product, once daily for 60 days</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>NVXT Solution</intervention_name>
    <description>NVXT Solution, applied to infected toe nails and 0.5 mm of adjacent skin once daily for 60 days.</description>
    <arm_group_label>NVXT Solution</arm_group_label>
    <other_name>NVXT</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Vehicle of test product</intervention_name>
    <description>Vehicle of test product applied to infected toe nails and 0.5 mm of adjacent skin once daily for 60 days.</description>
    <arm_group_label>Vehicle of test product</arm_group_label>
    <other_name>Placebo</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Clinically diagnosed onychomycosis

          -  Presence of dermatophyte fungal infection with no current topical or systemic
             antifungal therapy

          -  Clinical diagnosis of mild-to-moderate fungal infection of at least one toe involving
             10-50% of the nail area, without involvement of one of the lunular proximal regions

          -  Positive potassium hydroxide mount preparation

          -  Positive fungal culture for a dermatophyte

        Exclusion Criteria:

          -  Nail or anatomical abnormalities of the toe that may interfere with evaluations or
             dosing compliance
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Taro Pharmaceuticals USA</last_name>
    <role>Study Director</role>
    <affiliation>Taro Pharmaceuticals USA Inc.</affiliation>
  </overall_official>
  <removed_countries>
    <country>United States</country>
  </removed_countries>
  <verification_date>May 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 27, 2014</study_first_submitted>
  <study_first_submitted_qc>January 21, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 22, 2015</study_first_posted>
  <last_update_submitted>May 3, 2017</last_update_submitted>
  <last_update_submitted_qc>May 3, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">May 5, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Mycoses</mesh_term>
    <mesh_term>Onychomycosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pharmaceutical Solutions</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <pending_results>
    <submitted>May 17, 2018</submitted>
  </pending_results>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

